Patients struggle to find affordable insulin despite Eli Lilly price cap: Report

Uninsured Americans are still having challenges accessing affordable insulin, despite Eli Lilly's decision to cap its generic version, Lispro, at $25 per vial, according to a report Sen. Elizabeth Warren's office released July 13. 

The report was based on survey responses from more than 300 U.S. pharmacies. 

The average cost of Lispro for uninsured patients was $97.51 — nearly four times higher than the $25 price cap set by Eli Lilly. In addition, 42 percent of the surveyed pharmacies did not have the lower-priced generic in stock.

Eli Lilly, Sanofi and Novo Nordisk — the nation's three largest insulin manufacturers — all announced insulin price cuts in March. While most of these price drops take effect in late 2023 and 2024, Eli Lilly rolled out a cap for Lispro this May. 

Editor's note: Becker's has reached out to Eli Lilly for comment and will update the article as more information becomes available. 

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy
.
 

Articles We Think You'll Like